Newcastle, UK, June 21, 2023 — A groundbreaking study led by Professor Ioakim Spyridopoulos of Newcastle University showcases the promising potential of TA-65®, a dietary supplement, in improving patient outcomes after a heart attack.
The research, conducted in collaboration with the heart team at The James Cook University Hospital in Middlesbrough, focused on the role of TA-65® in combating immunosenescence — the aging of the immune system — and reducing inflammation, a critical factor in heart attack and subsequent complications.
Reducing inflammation is a key treatment target following a heart attack. Remarkably, the study, published in GeroScience, revealed that TA-65® not only significantly reduced inflammation by up to 62%, but also increased the number of immune cells, enhancing the immunity of patients.
Highlighting the distinctness of TA-65®, Spyridopoulos stated, "Unlike most potent anti-inflammatory drugs that suppress the immune system and increase the risk of severe infections, the widely available health supplement TA-65® appears to reduce inflammation while concurrently improving immunity."
Furthermore, TA-65® has shown potential benefits for mitochondrial health, contributing to the overall vitality and wellness of individuals, particularly those recovering from myocardial infarction. As the 'powerhouses' of cells, healthy mitochondria play a crucial role in the body's overall health and resilience, which makes the benefits of TA-65 in this area particularly promising.
"TA-65's demonstrated safety profile and significant health benefits make it a valuable new addition to the toolkit for managing the common issue of immunosenescence following a heart attack," said Spyridopoulos.
TA-65® is widely accessible to those who can benefit from its health-enhancing properties and is available for purchase through T.A. Sciences® on their website www.tasciences.com, as well as through healthcare professionals.